Avelumab and Merkel Cell Carcinoma Prognosis: Is the Effect Permanent?

From General Health Guidance to Targeted Exposure Concerns

For decades, public health communication has centered on general wellness principles—balanced nutrition, routine screening, and the avoidance of known carcinogens such as tobacco and ultraviolet radiation. This foundational framework has successfully guided populations toward reduced disease risk, particularly in the context of skin malignancies. Within this legacy, the role of environmental and occupational exposures has been acknowledged but often treated as secondary to lifestyle factors. However, as therapeutic landscapes evolve, new vectors of chemical exposure emerge that demand a shift in focus. One such vector is the increasing use of immunomodulatory agents in clinical settings, which introduces a novel dimension to risk assessment. Specifically, the administration of Avelumab—a programmed death-ligand 1 inhibitor—has become a standard intervention for advanced Merkel cell carcinoma. While its therapeutic benefits are well-documented, the question of whether such exposure can permanently alter disease trajectory or confer lasting risk remains underexplored. This gap is particularly salient for healthcare workers and patients who encounter Avelumab in occupational or clinical contexts. The transition from general health guidance to a targeted concern about Avelumab exposure and Merkel cell carcinoma prognosis requires careful parsing of exposure duration, immune modulation, and long-term outcomes.

Understanding Avelumab and Its Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This raises the question of whether the effects of avelumab on MCC are permanent, and what the prognosis is for patients who experience progression or adverse events.

Evidence on Permanence and Prognosis

The prognosis for MCC is generally poor due to its high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab is the first therapeutic agent specifically approved for metastatic MCC, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). While it can induce durable responses, the permanence of these responses is not guaranteed. Evidence from multiple studies indicates that avelumab-refractory MCC is a recognized clinical scenario. For example, a retrospective study at three German sites enrolled five patients with metastatic MCC who were refractory to avelumab and later treated with combined ipilimumab and nivolumab (IPI/NIVO); three of these five patients responded to the combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Similarly, a multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62%, but it also highlighted the existence of avelumab-refractory cases (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study noted that despite the approval of avelumab and pembrolizumab for advanced MCC, about 50% of patients progress on ICI therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). These findings suggest that while avelumab can produce durable responses in some patients, it does not provide permanent cure for all, and progression or refractoriness is a significant concern.

Mechanisms and Adverse Events

The mechanistic pathway linking avelumab to MCC involves its action as an anti-PD-L1 inhibitor, which blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby reactivating the immune system to attack cancer cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, this immune activation can also lead to immune-related adverse events (irAEs). A case report described hypercalcemia due to reactivation of sarcoidosis during treatment with avelumab for metastatic MCC; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while avelumab can be effective, it carries risks of irAEs that may require intervention but are not necessarily permanent.

Clinical Implications and Monitoring

Regarding the adequacy of warnings, the evidence indicates that avelumab is approved for metastatic MCC and is associated with both benefits and risks. The JAVELIN Merkel 200 trial provided data on efficacy, but the occurrence of avelumab-refractory disease and irAEs suggests that clinicians and patients should be aware of the possibility of progression and adverse effects. The timeline between exposure and documented harm varies. In the case of hypercalcemia due to sarcoidosis, the adverse event occurred during treatment and resolved with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). For avelumab-refractory MCC, the timeline is less clear but typically involves progression after initial response or stable disease, as seen in the studies where patients were treated with subsequent therapies after avelumab failure (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The prognosis for affected patients depends on their response to avelumab and subsequent treatments. For those who progress, combination therapy with ipilimumab and nivolumab has shown promise, with three out of five patients responding in one study (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, the overall prognosis remains guarded due to the aggressive nature of MCC. In summary, avelumab is not a permanent cure for MCC; it provides durable responses in a subset of patients, but approximately half of patients may progress. The prognosis for MCC remains poor overall, and avelumab-refractory disease is a recognized challenge. Adequate warnings should include the risk of progression and irAEs, which are manageable but not always permanent. The timeline for harm can occur during treatment, as with irAEs, or after initial response, as with refractoriness. Clinicians should monitor patients closely and consider alternative therapies for those who progress.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Is Merkel cell carcinoma caused by Avelumab permanent?

No, Merkel cell carcinoma (MCC) is not caused by Avelumab; Avelumab is a treatment for MCC. The question likely refers to whether the effects of Avelumab on MCC are permanent. Evidence shows that while Avelumab can induce durable responses in some patients, it does not provide a permanent cure for all. Approximately 50% of patients may progress on therapy, and avelumab-refractory disease is a recognized clinical scenario (https://pubmed.ncbi.nlm.nih.gov/35877101/).

What is the prognosis for Merkel cell carcinoma patients treated with Avelumab?

The prognosis for MCC remains generally poor due to high rates of recurrence and mortality. Avelumab can improve outcomes in a subset of patients, with objective response rates around one-third in chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, about half of patients may progress, and the overall prognosis is guarded. Combination therapies like ipilimumab and nivolumab have shown promise in avelumab-refractory cases (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.